Fresh Tracks Therapeutics, Inc.

OTCPK:FRTX Stock Report

Market Cap: US$4.4m

Fresh Tracks Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Fresh Tracks Therapeutics has a total shareholder equity of $9.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $11.6M and $1.7M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$10.87m
EquityUS$9.93m
Total liabilitiesUS$1.66m
Total assetsUS$11.59m

Recent financial health updates

Recent updates

Brickell Biotech changes name to Fresh Tracks Therapeutics

Sep 07

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Aug 11

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Jul 20

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Feb 14
Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Brickell Biotech Advances To Phase III As It Eyes Commercialization

May 10

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

Apr 27

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Jan 06
Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Brickell Biotech (BBI) Investor Presentation - Slideshow

Dec 02

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26

Nov 18

Financial Position Analysis

Short Term Liabilities: FRTX's short term assets ($11.6M) exceed its short term liabilities ($1.7M).

Long Term Liabilities: FRTX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: FRTX is debt free.

Reducing Debt: FRTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if FRTX has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FRTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:35
End of Day Share Price 2024/12/23 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fresh Tracks Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Thomas FlatenLake Street Capital Markets, LLC
Leland GershellOppenheimer & Co. Inc.